

EPD 09/15/2003

Appl. No. 10/663,407
Amdt. dated November 17, 2006
Reply to Notice to Comply of October 17, 2006

PNAS 2001
98(4): 7724

1) ~~REMARKS~~ 11/17/06 O.K.

2) IDG 11/15/04

3) 306 copy.

4)

IN THE CLAIMS 20-27

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

Claim 1-19 (cancelled)

summarized susceptibility gene 101
✓
H2A1.2 (Tsg101)
→ GAG p16

1) Tsg101 means
p16 GAG

Claim 20 (new): A method of inhibiting the binding of Tsg101 to HIV GAG comprising contacting Tsg101 with an antibody immunoreactive with the UEV domain of Tsg101, in the presence of said HIV GAG, wherein said antibody inhibits said binding.

in vitro
in vivo

ubiquitin E2 variant
(UEV)

Claim 21 (new): The method of claim 20, wherein said binding of Tsg101 to HIV GAG occurs between the UEV domain of Tsg101 and the (late domain) of HIV GAG.

621AP → ? late domain
LATE ASSUMED
DOMAIN

Claim 22 (new): The method of claim 20, wherein said antibody is selectively immunoreactive with the UEV domain of Tsg101.

Claim 23 (new): The method of claim 20, wherein said antibody is a polyclonal antibody.

Claim 24 (new): The method of claim 20, wherein said antibody is a monoclonal antibody.

Claim 25 (new): The method of claim 20, wherein said antibody is an antibody fragment.

Claim 26 (new): The method of claim 20, wherein said antibody is a single chain antibody. SCFV

* PROPHETIC SEQ; NO DATA OR EXAMPLES;

Anti Tsg-101
immunoreactive Abs

US 2003 138839
US 2002 034243

* US 2002 048706 Abs (all donors)

Ab 1.97

21
22
23
24

Appl. No. 10/663,407
Amdt. dated November 17, 2006
Reply to Notice to Comply of October 17, 2006

Claim 27 (new): The method of claim 20, wherein said antibody is a humanized antibody.